| Jul 10 |
Wall Street Analysts Think uniQure (QURE) Could Surge 195.8%: Read This Before Placing a Bet
|
| Jul 10 |
uniQure (QURE) Soars on New Huntington's Disease Study Data
|
| Jul 10 |
uniQure (QURE) Surges 76.5%: Is This an Indication of Further Gains?
|
| Jul 9 |
S&P 500 Edges Higher; Indivior Shares Plummet
|
| Jul 9 |
uniQure: Positive HD AMT-130 Treatment Data Leads To Several Other Catalysts
|
| Jul 9 |
Down -29.74% in 4 Weeks, Here's Why You Should You Buy the Dip in uniQure (QURE)
|
| Jul 9 |
UniQure stock surges on data for Huntington’s gene therapy
|
| Jul 9 |
uniQure updates trial data for Huntington’s disease therapy
|
| Jul 9 |
uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease
|
| Jul 1 |
uniQure N.V. (NASDAQ:QURE) is a favorite amongst institutional investors who own 52%
|
